C57BL/6-IL33tm1(hIL33)Bcgen/Bcgen • 110055
| Product name | B-hIL33 mice |
|---|---|
| Catalog number | 110055 |
| Strain name | C57BL/6-IL33tm1(hIL33)Bcgen/Bcgen |
| Strain background | C57BL/6 |
| NCBI gene ID | 90865 (Human) |
| Aliases | DVS27; IL1F11; NF-HEV; NFEHEV; C9orf26 |
Gene targeting strategy for B-hIL33 mice. The exons 2-8 of mouse Il33 gene that encode the full-length protein were replaced by human IL33 exons 2-8 in B-hIL33 mice.
Airways from B-hIL33 mice exposed to PBS aerosols did not show any inflammation. OVA exposure resulted in a significant increase in peribronchial and perivascular inflammatory infiltrates, as well as increase in the level of mucus secretion. A reduction in inflammatory infiltrates and mucus secretion was observed in mice treated with etokimab analog.
The number of BALF immune cells in acute mouse asthma model
BALF immune cell profiles in acute mouse asthma model. BALF Immune cells were isolated from B-hIL33 mice (n=5). The number of eosinophils were deterimined by flow cytometry in acute asthma mice treated with or without etokimab anolog. Treatment of etokimab analog almost completely abolished the inflammatory cells in homozygous B-hIL33 mice as opposed to in untreated mice.
IgE production in mouse asthma model
IgE production. Serum was collected at the study endpoint. IgE levels responded to OVA-specific antibody were analyzed. The results show that the levels of IgE in mice treated with etokimab is much lower than that in untreated mice.
